Evofem Biosciences Updates Principal Executive Office Address
Ticker: EVFM · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1618835
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative-change
TL;DR
**Evofem Biosciences changed its main office address, a minor but notable operational update.**
AI Summary
Evofem Biosciences, Inc. filed an 8-K on February 1, 2024, to update its principal executive offices to 7770 Regents Road, Suite 113-618, San Diego, CA 92122. This change in address, while seemingly minor, is important for investors as it ensures they have the most current contact information for the company, which trades under the symbol EVFM on the OTCQB, and reflects operational adjustments that could impact administrative efficiency.
Why It Matters
This filing provides updated contact information for Evofem Biosciences, ensuring investors and regulators have the correct address for official communications. It reflects a minor operational change that could signal cost-saving measures or a shift in company structure.
Risk Assessment
Risk Level: low — Changing a business address is a routine administrative task and does not inherently pose significant financial or operational risk to the company.
Analyst Insight
Investors should update their records with the new contact information for Evofem Biosciences, but this administrative change alone does not warrant any immediate investment action.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — the registrant filing the 8-K
- 7770 Regents Road, Suite 113-618 San Diego, CA 92122 (address) — the new principal executive offices
- February 1, 2024 (date) — date of earliest event reported
- EVFM (ticker) — trading symbol for Common Stock
- OTCQB (exchange) — exchange where Common Stock is registered
Forward-Looking Statements
- Evofem Biosciences will continue to operate from its new San Diego address. (Evofem Biosciences, Inc.) — high confidence, target: 2025-02-01
FAQ
What is the primary purpose of this 8-K filing by Evofem Biosciences, Inc.?
The primary purpose of this 8-K filing is to report a change in the principal executive offices of Evofem Biosciences, Inc. to 7770 Regents Road, Suite 113-618, San Diego, CA 92122, as of February 1, 2024.
What was the previous address for Evofem Biosciences, Inc. mentioned in the filing?
The filing indicates the previous business address was 12400 High Bluff Drive, Suite 600, San Diego, CA 92130, which is now updated to 7770 Regents Road, Suite 113-618, San Diego, CA 92122.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 1, 2024.
What is the trading symbol and exchange for Evofem Biosciences, Inc.'s Common Stock?
Evofem Biosciences, Inc.'s Common Stock trades under the symbol EVFM on the OTCQB exchange.
Does this 8-K filing contain any financial statements or results of operations?
While the 'ITEM INFORMATION' section lists 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', the body of this specific 8-K filing only details the change in address and does not provide actual financial statements or results of operations.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-02-01 09:05:13
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share EVFM OTCQB Indicate by
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-004575.txt ( ) — 224KB
- evfm-20240201.xsd (EX-101.SCH) — 3KB
- evfm-20240201_lab.xml (EX-101.LAB) — 33KB
- evfm-20240201_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Date: February 1, 2024 By: /s/ Ivy Zhang Ivy Zhang Chief Financial Officer